Patients

The identification of the schizophrenic population has been described in detail previously (Reference McCreadieMcCreadie, 1982; Reference Kelly, McCreadie and MacEwanKelly et al, 1998). Briefly, repeat censuses in Nithsdale (population 57 000) in south-west Scotland have on many occasions over the years identified all patients with schizophrenia. Patients in the present study were identified on 1 April 1998. They included all inpatients, day patients and out-patients known to Crichton Royal Hospital on the census date who had an ICD-10 diagnosis of schizophrenia (World Health Organization, 1992) and whose home address was in Nithsdale. General practitioners (GPs) in the Nithsdale area were given a list of patients with schizophrenia in their practice and asked to update it; all general practitioners replied. In addition, community psychiatric nurses, voluntary agencies and social workers were asked to identify any other patients with schizophrenia. Over the years, this ‘key informant’ method has allowed us to identify, trace and interview such patients in Nithsdale.

The ICD-10 diagnosis of schizophrenia is broad; however, a 1997 Nithsdale study (Reference McCreadie, Leese and Tilak-SinghMcCreadie et al, 1997) showed that 87% of patients with a clinical diagnosis of schizophrenia also fulfilled OPCRIT-derived DSM-III-R criteria (Reference McGuffin, Farmer and HarveyMcGuffin et al, 1991).

The census identified 182 patients, 96 (53%) male and 86 (47%) female. Of these, 9% were long-stay and 5% acute inpatients, 20% were day patients, and 34% out-patients, 17% mainly had contact with the community psychiatric nurse and 15% had contact with the GP only. As a prevalence study, the population included patients whose illness varied greatly in chronicity and severity. No patients had received electroconvulsive therapy in the preceding 12 months. Informed consent was obtained for all subjects before participation.

Assessment of cognitive function

Measures were chosen for their shortness, ease of use and acceptability to patients. Cognition was assessed using a battery of five cognitive measures.

1. (a) The National Adult Reading Test (NART), which gives an estimate of premorbid IQ (Reference NelsonNelson, 1982). The NART has been assessed in patients with schizophrenia and been shown to be a valid measure of premorbid IQ (Reference Crawford, Besson and BremnerCrawford, et al, 1992).

2. (b) The Mini-Mental State Examination (MMSE), a well-established screening test for cognitive impairment (Reference Folstein, Folstein and McHughFolstein et al, 1975). The MMSE has been used as a broad test of global cognitive function in schizophrenia and shown to be reliable and stable (Reference Harvey, White and ParrellaHarvey et al, 1995). A score of <24 is indicative of significant global cognitive impairment.

3. (c) The Rivermead Behavioural Memory Test (RBMT), a measure of everyday memory (Reference Wilson, Cockburn and BaddelyWilson et al, 1989). The RBMT was initially designed for a brain-injured population, but has also been shown to be a useful measure of memory function in subjects with schizophrenia (Reference McKenna, Tamlyn and LundMcKenna et al, 1990). Two scores can be obtained: a screening score (0-12) and a standardised profile score (0-24). Based on scores, patients can be categorised as having normal, poor, moderately impaired or severely impaired memory.

4. (d) The Executive Interview (EXIT) (Reference Royall, Mahurin and GrayRoyall et al, 1992), a measure of the behavioural consequences of executive dyscontrol, which correlates well with established tests of executive functions such as the Wisconsin Card Sorting Test (Reference BergBerg, 1948). It was designed for an elderly population but has been shown to be a reliable screening test in a schizophrenia group (Reference Scully, Coakley and KinsellaScully et al, 1997). It has 25 items, and the score ranges from 0 to 50; a score of >15 indicates executive dyscontrol.

5. (e) The Initial Letter Verbal Fluency Test (FAS), an assessment of executive (frontal) function and semantic memory store (a temporal lobe function) (Reference Parker, Crawford, Crawford, McKinlay and ParkerParker & Crawford, 1992). In a timed test, the patient generates words beginning with the letters F, A and S. A score of <30 indicates reduced verbal fluency. The FAS and the Wisconsin Card Sorting Test have been shown to be the best validated tests of executive (frontal) function, and have been used widely with normal controls and with subjects with schizophrenia (Reference Crawford, Obonsawin and BremnerCrawford et al, 1993).

All cognitive measures were administered by a research nurse (V.S.), trained in the use of the scales; a session lasted about 40 minutes.

Social disability and community functioning over the preceding 2 weeks were assessed by the Health of the Nation Outcome Scales (HoNOS; Reference Wing, Beevor and CurtisWing et al, 1998). HoNOS is a simple, brief and clinically acceptable instrument based on an interview with the keyworker.

Statistical analysis

Differences between groups were examined by t-tests and analysis of variance (ANOVA); Pearson's r was used to examine correlations.

Educational history

Fifty-nine per cent of the patients had completed secondary school education only, 23% had attended college or technical training, a further 11% had attended vocational training (e.g., for nursing or teaching) and 7% had started university education. Fifty-two per cent of the patients had obtained no qualifications, 32% had passed the secondary school examination, 9% had obtained college or technical qualifications and 7% had completed teacher or nurse training or obtained a university degree.

Cognitive measures

Cognition was assessed in 138 of 182 patients (response rate 76%). There was no difference in age or gender between responders and non-responders: 52% of responders were male; demographic and clinical variables by gender are shown in Table 1.

Table 1

Demographic and clinical data and cognitive scores by gender

	Male			Female
	n	Mean	s.d.	n	Mean	s.d.
Age (years)	72	46	14	66	51	18
Age range (years)	72	23-76		66	20-90
Age at onset of illness (years)	72	27	9	66	29	13
NART IQ	68	98	14	64	98	14
MMSE1	72	27	4	66	26	4
RBMT1	72	7	3	63	6	3
EXIT2	72	11	7	65	12	7
FAS1	71	26*	13	65	21*	13

One hundred and thirty-two patients completed the NART. The mean Wechsler Adult Intelligence Scale—Revised (WAIS—R; Reference WechslerWechsler, 1981) IQ generated from the NART error score was 98 (s.d. 14, range 69-126).

On the MMSE, 15% of patients showed significant global cognitive impairment; on the RBMT, 81% showed memory impairment; on the EXIT (n=137) 25% showed executive dyscontrol; and on the FAS (n=136) 49% had reduced verbal fluency. Figure 1 shows the distribution of scores for the MMSE (n=138) and RBMT (n=135).

Fig. 1

Distribution of scores for Mini-Mental State Examination (MMSE) (n=138) and Rivermead Behavioural Memory Test (RBMT) (n=135).

Table 1 shows cognitive measures for both genders; scores were similar except in the FAS, where men scored significantly higher.

Cognition and age

Cognition scores for patients in each of six age bands are shown in Table 2. Three women, aged 80, 89 and 90 years, were excluded from this analysis. There were no between-group differences in the NART IQ, but there were significant between-group differences in scores on the MMSE, RBMT, EXIT and FAS. Performance was poorest in the over-60 age groups.

Table 2

Cognitive measures by 10-year age bands

Age bands4	n 1	Male/female ratio	NART IQ		MMSE2		RBMT2		EXIT3		FAS2
			Mean	(s.d.)	Mean	(s.d.)	Mean	(s.d.)	Mean	(s.d.)	Mean	(s.d.)
20-29	17	7/10	97	(9)	28	(2)	7	(2)	7	(3)	31	(11)
30-39	31	19/21	100	(11)	28	(2)	8	(2)	8	(5)	27	(11)
40-49	29	19/10	97	(13)	26	(3)	7	(3)	12	(7)	25	(13)
50-59	28	16/12	102	(16)	27	(2)	8	(2)	10	(5)	24	(9)
60-69	16	4/12	92	(3)	23	(5)	4	(3)	18	(7)	14	(11)
70-79	14	7/7	94	(20)	23	(6)	4	(3)	16	(7)	19	(14)

Community status

The relationship between patients' community status (i.e., in-patient, out-patient, etc.) and cognitive results is shown in Table 3. There were significant between-group differences in scores on the MMSE, RBMT and EXIT. Long-stay in-patients scored lowest, and worse than patients of comparable age supported only by GP care.

Table 3

Cognitive measures by community status

Community status4	n 1	Male/female ratio	Age (years)		NART IQ		MMSE2		RBMT2		EXIT3		FAS2
			Mean	(s.d.)	Mean	(s.d.)	Mean	(s.d.)	Mean	(s.d.)	Mean	(s.d.)	Mean	(s.d.)
In-patient (long-stay)	15	6/9	58	(18)	92	(20)	23	(7)	4	(3)	17	(9)	20	(15)
In-patient (acute)	9	7/2	43	(18)	92	(14)	26	(3)	5	(3)	11	(6)	21	(9)
Day-patient	27	15/12	41	(13)	98	(13)	28	(2)	7	(3)	11	(6)	27	(14)
Out-patient	48	28/20	43	(13)	99	(11)	27	(3)	7	(3)	9	(6)	25	(12)
Community psychiatric nurse care	23	12/11	55	(13)	97	(15)	25	(5)	6	(3)	13	(7)	21	(12)
General practitioner care	16	5/11	59	(17)	107	(12)	26	(4)	8	(3)	12	(7)	23	(12)

HoNOS

Keyworkers of 47 of the patients were available for interview. The HoNOS has four sub-scales which assess behaviour, functional impairment, symptoms and social circumstances; a higher score indicates more disability. In the functional impairment sub-scale, the keyworkers rated 27% of the patients as having problems in the community owing to poor cognition (memory, orientation and understanding). There were significant correlations between cognitive measures and the functional impairment sub-scale of HoNOS; MMSE (Pearson's r=-0.4, P<0.01), RBMT (r=-0.5, P<0.001), EXIT (r=0.4, P<0.01) and FAS (r=-0.4, P<0.01). Figure 2 shows the relationship between memory measured by RBMT and functional impairment measurement by HoNOS; the poorer the score on memory, the worse was the functional impairment.

Fig. 2

Relationship between memory impairment (Rivermead Behavioural Memory Test (RBMT) screening score) and disability on functional impairment sub-scale of Health of the Nation Ouctome Scales (HoNOS).

Cognitive dysfunction

There was a high prevalence of cognitive dysfunction in our community-based population of patients with schizophrenia. Memory impairment was most obvious, with 81% affected. Fifteen per cent of the patients showed significant global cognitive impairment on the MMSE, while at least a quarter had executive (frontal) dysfunction. This high level of current cognitive dysfunction was present despite the fact that their premorbid IQ and schooling were predominantly normal. Other studies (e.g., Reference Crawford, Besson and BremnerCrawford et al, 1992) have found that people with schizophrenia perform similarly to control subjects on the NART. The only gender difference was in the FAS, where the women scored lower. This may be explained by the difference in mean age (5 years between the men and the women subjects); there is a high negative correlation between FAS performance and age (Reference Crawford, Obonsawin and BremnerCrawford et al, 1993).

Our estimate of the prevalence and pervasiveness of memory problems in the Nithsdale population is almost identical to that of McKenna et al (Reference McKenna, Tamlyn and Lund1990), who investigated memory impairment in 60 patients with schizophrenia from acute, rehabilitation and long-stay services; in addition, similar proportions of patients in both studies are classed as having global cognitive impairment on the MMSE.

The numbers of patients with frontal dysfunction, as estimated by the FAS initial letter verbal fluency test (49%), were double those obtained using the EXIT interview (25%). Cut-off points, of course, are arbitrary. Also, the FAS is a timed test; poor performance by people with schizophrenia may be due to other factors, such as slowness or current psychotic symptoms, including thought disorder. The EXIT is designed for elderly or brain-damaged patients and allows for poor concentration and motivation.

When does cognitive decline occur?

There is much debate about when cognitive decline occurs in schizophrenia, and whether it is progressive or static. Some studies suggest that deficits in intellectual function are lifelong and pre-date (and may predispose to) the onset of schizophrenia (Reference Russell, Munro and JonesRussell et al, 1997). Other studies, which have examined first-episode, drugnaïve patients, reported clear neuropsychological deficits similar to those found in more chronic medicated patients (Scottish Schizophrenia Research Group, 1987). It has also been suggested that after a period of initial deterioration early in the illness, cognitive deficits become static (Reference Hyde, Nawroz and GoldbergHyde et al, 1994). Finally, it has been suggested that as schizophrenia becomes more severe and chronic, impairment becomes more widespread and clearly detectable, and amounts to dementia in some individuals (Reference Scully, Coakley and KinsellaScully et al, 1997).

While we should be cautious about making longitudinal interpretations of cross-sectional studies, the Nithsdale results suggest that older people (over 60 years of age) with schizophrenia show a poorer cognitive performance than younger patients. Our results are in direct contrast to those of Hyde et al (Reference Hyde, Nawroz and Goldberg1994), who, in a cross-sectional study, reported no decline in cognitive function across five 10-year age cohorts (20-70 years). The apparent difference may be explained by the difference between the two groups studied: our study represents a whole population of patients, while Hyde and colleagues examined a highly selected group (522 screened to yield 74), from which patients who had conditions which might have an adverse impact on the central nervous system were excluded. In a recent shortterm (30-month) follow-up of geriatric long-stay patients with schizophrenia, cognitive and functional decline was detected (Reference Harvey, Silverman and MohsHarvey et al, 1999).

The mechanism underlying poor cognition in schizophrenia is unclear, and most work has failed to indicate a specific schizophrenic pathological process. However, many of the exclusion criteria employed by Hyde et al (Reference Hyde, Nawroz and Goldberg1994) included comorbidity and treatments (such as substance misuse and hypertension, and electroconvulsive therapy) that are intimately associated with the schizophrenic illness process. These, as well as poor physical health and heavy cigarette smoking (Reference Kelly and McCreadieKelly & McCreadie, 1999), may contribute to a premature aging process that can lead to earlier and accelerated cognitive decline.

Cognition and community functioning

The long-stay in-patient group clearly performed worse on all cognitive measures than did patients of a similar age in contact only with their family doctor. This finding is in keeping with previous studies which have examined large groups of chronic in-patients (Reference Owens and JohnstoneOwens & Johnstone, 1980).

While there has been much discussion about the range and nature of cognitive deficits, there has been less emphasis on their functional consequences. We used the HoNOS to assess community functioning. The HoNOS has recently been the subject of intensive scrutiny (British Journal of Psychiatry, 1999, 174, 380-438). It is not without its defects, but is gaining a place as another symptom and social function inventory, “ better than most” (Reference SteinStein, 1999). Our study showed a clear relationship between the functional impairment sub-scale of HoNOS and poor performance on current cognitive measures. The functional sub-scale is an assessment of problems in the community caused by poor cognition (memory, orientation and understanding) and physical illness or disability. The consequences of cognitive deficits were severe enough to be detected in a routine clinical setting by keyworkers, mainly community psychiatric nurses.

We conclude that cognitive dysfunction is a core disability in schizophrenia, affecting the majority of patients. Neuropsychological evaluation is rarely used in planning rehabilitation, yet cognitive deficits are likely to be a limiting factor in terms of functioning as a member of the community. If there is greater awareness of the prevalence and pervasiveness of cognitive dysfunction in schizophrenia and the ensuing disabilities, we may be able to help our patients function more effectively in the community. In Nithsdale we are now trying to engage some of our patients in cognitive remediation, a technique which, applied in schizophrenia, is in its infancy (Reference O'Carroll, Russell and LawrieO'Carroll et al, 1999).

CLINICAL IMPLICATIONS

• ▪ Cognitive dysfunction, particularly memory impairment, is a widespread and core disability in the majority of patients with schizophrenia.

• ▪ Cognitive dysfunction has a major impact on patients' daily lives and is likely to limit their functioning in the community.

• ▪ Cognitive evaluation and remediation should become important approaches in the management of patients with schizophrenia.

LIMITATIONS

• ▪ The neuropsychological battery of tests was short.

• ▪ A cross-sectional design limits speculation about longitudinal cognitive decline.

• ▪ The Health of the Nation Outcome Scales assessment was only available for one-third of the subjects.